LONDON and BOSTON, May 29, 2014 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that Malcolm Weir, Heptares' Chief Executive Officer and co-founder, will give a company presentation at the Jefferies 2014 Global Healthcare in New York City, NY, USA. The presentation will take place at 9:00am EDT on Monday 2 June.

In addition, Heptares will give presentations at the following industry and scientific meetings over the coming weeks:

Boston CEO Conference (Boston, MA, USA, 4-6 June)

Dan Grau, Heptares President, will participate in a panel discussion entitled "2014 Healthcare Market Outlook" at 4:30pm EDT on Wednesday 4 June.

BIO 2014 International Convention (San Diego, CA, USA, 23-26 June)

Dan Grau will present an overview of the Company during the BioBusiness Forum at 3:15pm PDT on 24 June in the Pacific Beach Room. Barry Kenny (Chief Business Officer) and Cath Hutchings (Antibody Alliance Management & Strategic Partnering) will also be present at the event.

IBC Next Generation Protein Therapeutics (San Francisco, CA, USA, 4-6 June)

Cath Hutchings (Antibody Alliance Management & Strategic Partnering) will give a presentation entitled "Using Stabilised Receptors as Antigens to Generate Therapeutic Antibodies to GPCR Targets," at 11:15am PDT on Friday 6 June.

RSC Chemical Biology Meets Drug Discovery 2014 (Windlesham, UK, 12 June)

Miles Congreve (VP Chemistry) will give a presentation entitled "Structure-Based Drug Discovery with Stabilised G Protein-Coupled Receptors."

For a full list of events at which Heptares will be present, please visit http://www.heptares.com

About Heptares Therapeutics 

Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;  

StaR is a registered trademark in the EU and Japan. 

Contact Information

Citigate Dewe Rogerson (for Heptares)
Mark Swallow, Chris Gardner
+44(0)20-7282-2948/2995
mark.swallow@citigatedr.co.uk
   
Heptares Therapeutics Ltd
Malcolm Weir, Chief Executive Officer (UK)
+44(0)1707-358-629
malcolm.weir@heptares.com

Dan Grau, President (USA)
+1-857-222-4586
dan.grau@heptares.com    

SOURCE Heptares Therapeutics